Bielenberg
Gerhard-Wilhelm Bielenberg, Alfeld DE
Patent application number | Description | Published |
---|---|---|
20100010062 | METHOD OF TREATMENT USING EPROSARTAN - The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan compound. With reference to the Recommended Effective Daily Dose of 600 mg, calculated on the basis of eprosartan administered in the form of eprosartan mesylate, it has now been found that a lower dose of eprosartan can be administered when the eprosartan compound is eprosartan acid. This dose is in the range of from 410 to 490 mg, most preferably about 450 mg. | 01-14-2010 |
Gerhard-Wilhelm Bielenberg, Hannover DE
Patent application number | Description | Published |
---|---|---|
20110229571 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker - Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes. | 09-22-2011 |
Gerhard-Wilhelm Bielenberg, Weesp NL
Patent application number | Description | Published |
---|---|---|
20120302555 | METHOD OF TREATMENT USING EPROSARTAN - The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan compound. With reference to the Recommended Effective Daily Dose of 600 mg, calculated on the basis of eprosartan administered in the form of eprosartan mesylate, it has now been found that a lower dose of eprosartan can be administered when the eprosartan compound is eprosartan acid. This dose is in the range of from 410 to 490 mg, most preferably about 450 mg. | 11-29-2012 |
Michael Bielenberg, Hamburg DE
Patent application number | Description | Published |
---|---|---|
20110234426 | Apparatus and method for pressurising an aircraft cabin structure and measuring the amount of leakage of the aircraft cabin structure - An apparatus ( | 09-29-2011 |